Apple Adds Blood Oxygen to Watch: Will Wearables' Top Line Rise?

Apple has introduced a redesigned Blood Oxygen feature for select Apple Watch models, aiming to revitalize its Wearables, Home and Accessories segment, which saw sales decline 8.6% year-over-year to $7.4 billion in Q3, albeit slightly beating consensus estimates. This move occurs amidst intensifying competition from rivals like Alphabet, which is integrating Gemini AI into Wear OS and securing FDA clearance for new health features, and Garmin, projecting over 25% fitness revenue growth in 2025 with its expanding health-centric smartwatches. Despite a premium forward P/E of 29.75x, Apple's shares have underperformed, falling 7.8% year-to-date against the broader tech sector's 13.9% gain.

Analysis

Apple is reintroducing a redesigned Blood Oxygen feature for its latest Watch models in an effort to stimulate its Wearables, Home and Accessories segment, which experienced an 8.6% year-over-year sales decline to $7.4 billion in Q3. While this figure marginally surpassed consensus estimates by 0.85%, the segment's performance highlights a significant challenge amid intensifying competition. Garmin is demonstrating strong momentum, projecting over 25% growth in fitness revenues for 2025, while Alphabet is bolstering its Wear OS platform with Gemini AI and new FDA-cleared health features. Financially, Apple's stock reflects these headwinds, having fallen 7.8% year-to-date and underperforming the tech sector's 13.9% gain. The stock trades at a premium forward P/E of 29.75x compared to the sector's 28.19x, earning it a poor Value Score of 'F'. Despite this, the consensus earnings estimate for fiscal 2025 has risen 3.2% over the past month, forecasting 8.6% year-over-year growth, indicating a potential disconnect between current segment struggles and broader earnings expectations.

Key Decisions for Investors

• Given the 8.6% decline in Apple's Wearables sales and intensifying competition, investors should monitor this segment's revenue contribution closely as a potential drag on overall growth, despite positive full-year earnings forecasts.
• With Apple's stock underperforming the sector while trading at a premium P/E of 29.75x, it may be prudent to weigh the projected 8.6% earnings growth against the risk of multiple compression if key segments fail to reignite growth.
• The strong competitive positioning and positive outlook for Garmin and Alphabet in the wearables market suggest they may be capturing market share, warranting consideration as alternative investments within the sector.
• The conflicting signals of declining segment sales versus rising earnings estimates support a cautious 'Hold' stance; investors should watch for a definitive turnaround in the Wearables business or a more attractive valuation entry point.